29 Jul 2015
(MENAFN) Jordan’s Hikma Pharmaceuticals said it is buying US generic drugs business of Boehringer Ingelheim for USD2.65 billion in a cash-and-stock deal, Arab News reported.
Hikma Pharmaceuticals, which produces and markets branded and non-branded generic and injectable drugs, said the Boehringer purchase would make it the sixth biggest provider of generic drugs in the US.
The move comes as the Jordanian firm is looking to expand in the US. It strengthened its injectable drugs business there when it bought manufacturing assets from Germany’s Boehringer last year.
“We won’t be the size of Teva and other big companies, but we will be bigger than many other companies that were ahead of us over the last five years,” Hikma CEO Said in a statement.
27 Jan 2025
BBK offers customers with exclusive Tas’heel and Mazaya Finance to own their dream home
15 Jan 2025
BBK Signs Strategic Partnership with Bahrain Airport Company to Develop “Express Cargo Village”
08 Jan 2025
Bank of Bahrain and Kuwait and Global Payment Services Deliver the First Advanced Fraud Prevention Solution for Wallet Provisioning in the Kingdom of Bahrain
26 Dec 2024
BBK proudly supports “Celebrate Bahrain” as a gold sponsor in cooperation with BTEA
17 Nov 2024
BBK and Asia Jewellers announce exclusive offers to its customers at Jewellery Arabia 2024
12 Nov 2024
BBK partners with Durrat Al Bahrain to offer exclusive financing for Jawhart Al Marjan
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more